



Birmingham's Soluble Therapeutics acquires Seattle company Dilyx Biotechnology

[BIRMINGHAM, Alabama](#) – Birmingham biotechnology company, Soluble Therapeutics, has acquired Seattle-based [Dilyx Biotechnologies](#) as a wholly-owned subsidiary.

Soluble Therapeutics is a biotechnology company, spun-out of UAB, that has developed a new method of optimizing protein solutions for use in biopharmaceutical, agricultural, or industrial applications.

The technology is called High-throughput self interaction chromatography (HSC).

Traditional methods of optimizing these protein solutions were time-consuming and costly. Soluble Therapeutics' devices and methods save labs and companies thousands of dollars and huge amounts of time. Both of which are invaluable in the field of medical research.

[I did a full write up on them a couple of months ago. You can go read that by clicking here.](#)

Dilyx's technology is similar to Soluble Therapeutics'. They have developed a line of protein solution screening kits that are available on the market now.

"[Dilyx's] products are more suited for early stage R&D of protein formulations and our product can refine the formulation to be clinically relevant." Said John McCarter, Director of Business Development at Soluble Therapeutics. "Formulations are developed for the same protein for many different stages of the R&D process and this technology allows us to be a part of all those stages of development."

The company will not only be marketing their own HSC technology, but also the screening kits made available by the Dilyx purchase.

With this acquisition, Soluble Therapeutics is making a marked transition to a product-based company with tools available to researchers across the spectrum of protein-solution development and biologics.

Source: http://www.al.com/business/index.ssf/2014/10/soluble_therapeutics_acquires.html

October 2nd 2014